MedTrace Logo

Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

NCT00547716 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-01-09

No results posted yet for this study

Summary

Hepatitis C virus infection is the most common blood-borne infection in the United States and is a leading cause of chronic liver disease affecting 130 million people around the world. It is estimated that 1.6% of the US population may be affected by Hepatitis C infection. The only recommended treatment that has been approved for your condition is the use of interferon and ribavirin. In patients with chronic Hepatitis C, there tends to be an accumulation of fat in the liver. Fatty liver has been associated with failure of treatment.

The accumulation of fat in the liver has been blamed on a particular type of fat called triglycerides. Fish oil, by reducing a type of fat called VLDL, can lower the triglyceride concentration by as much as 50 percent or more. This study seeks to determine if the administration of fish oil along with standard treatment to patients with Hepatitis C will increase the treatment response rates.

Conditions

  • Hepatitis C

Interventions

DIETARY_SUPPLEMENT

Omega-3 Fatty Acids

Omega-3 Fatty Acids - 4 grams per day

DRUG

Placebo comparator

Sponsors & Collaborators

  • Reliant Pharmaceuticals

    collaborator INDUSTRY

  • Saint Luke's Health System Foundation

    collaborator UNKNOWN

  • Truman Medical Center

    collaborator OTHER

  • University of Missouri, Kansas City

    lead OTHER

Principal Investigators

  • Laura M Alba, M.D. · Truman Medical Center

  • Jagdish Nachnani, MD · Truman Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547716 on ClinicalTrials.gov